Every 10-Q that Inovio Pharmaceu (INO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow INO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INO filings page.
Inovio Pharmaceuticals reported a net loss of $6.0 million for the quarter and $25.7 million for the first half of 2026, both markedly narrower than the prior-year periods, helped by lower R&D and G&A spending and a $13.9 million non‑cash gain from remeasuring warrant liabilities. Cash and cash equivalents were $31.5 million and short‑term investments $5.1 million at June 30, 2026, with operating cash outflow of $39.6 million in the first half.
The company has an accumulated deficit of $1.84 billion, stockholders’ equity of $4.4 million, and management states there is substantial doubt about its ability to continue as a going concern beyond the first quarter of 2027 without additional capital. Recent equity and warrant offerings in April and July 2026 provided roughly $34.4 million in net proceeds and expanded common shares outstanding to 103.4 million as of August 10, 2026.
Inovio’s lead DNA medicine candidate, INO‑3107 for recurrent respiratory papillomatosis, showed a reduction in surgical interventions in 81.3% of Phase 1/2 trial patients, and the company believes it meets criteria for FDA accelerated approval, though the FDA may disagree, potentially requiring a costly Phase 3 trial. The business remains early‑stage, with no product revenue and significant dependence on regulatory success, external financing, and collaborations.
Inovio Pharmaceuticals (INO) reported Q3 2025 results with a net loss of $45.5 million (basic/diluted EPS $(0.87)) versus a loss of $25.2 million a year ago. Operating expenses declined year over year as research and development was $13.3 million (vs. $18.7 million) and general and administrative was $7.9 million (vs. $8.6 million). A $22.5 million increase in the fair value of warrant liabilities drove a sizeable other expense.
Cash and cash equivalents were $36.6 million and short-term investments were $14.2 million, totaling $50.8 million at September 30, 2025. Stockholders’ equity was $(7.7) million, down from $68.5 million at year-end 2024, reflecting cumulative losses and warrant liability remeasurement. Management states available liquidity is expected to support planned operations into the second quarter of 2026, and there is substantial doubt about the ability to continue as a going concern beyond the first quarter of 2026. The company closed a July 2025 equity-and-warrants financing with net proceeds of $22.4 million.
Inovio Pharmaceuticals, Inc. is a clinical-stage biotechnology company developing DNA medicines and CELLECTRA delivery devices, with lead candidate INO-3107 for recurrent respiratory papillomatosis (RRP). In a completed Phase 1/2 trial of INO-3107, 81.3% of patients experienced a reduction in the number of surgical interventions in the year following treatment versus the year prior.
For the quarter and six months ended June 30, 2025, the company reported net losses of $23.5 million and $43.2 million, respectively, with net loss per share of $0.61 for the quarter and $1.12 year-to-date. Cash and cash equivalents were $24.35 million and short-term investments were $23.20 million (combined $47.5 million). Working capital was $21.0 million, total assets $68.24 million, total stockholders' equity $28.53 million, and accumulated deficit $1.773 billion.
The company disclosed substantial doubt about its ability to continue as a going concern beyond Q2 2026, but closed a July 7, 2025 underwritten public offering that generated $22.5 million of net proceeds. Management resolved a prior manufacturing issue for a CELLECTRA disposable component and completed Design Verification testing.